

Steve Sisolak  
Governor  
Richard Whitley, MS  
Director



**DEPARTMENT OF  
HEALTH AND HUMAN SERVICES**  
Division of Health Care Financing and Policy  
*Helping people. It's who we are and what we do.*



Suzanne Bierman, JD, MPH  
Administrator

**Silver State Scripts Board**

**Meeting Minutes**

**Date of Meeting:** Thursday, June 23, 2022, at 1:00 PM

**Name of Organization:** The State of Nevada, Department of Health and Human Services, Division of Health Care Financing and Policy (DHCFP), Silver State Scripts Board.

Agenda Item	Record	Notes																														
<b>Closed Executive Session</b>																																
Financial Review of Drug Classes with Proposed Changes	<p>Chairman Decerbo called the meeting to order at 1:13 PM on June 23, 2022.</p> <p>Roll was taken by Chairman Decerbo.</p> <table style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 70%;"></th> <th style="width: 15%; text-align: center;">Present</th> <th style="width: 15%; text-align: center;">Absent</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>Adashek, Joseph, MD</td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>Gonzalez, Elizabeth, Pharm.D.</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>Niezborala, Isabella, Pharm.D.</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>Singh, Aditi, MD</td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> </tbody> </table>		Present	Absent	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Adashek, Joseph, MD	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Gonzalez, Elizabeth, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Niezborala, Isabella, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Singh, Aditi, MD	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<p><b>The DHCFP Staff Present were as follows:</b>  Olsen, David, Social Services Chief III  Gudino, Antonio, Social Services Program Specialist III  Griffin, Karen, Senior Deputy Attorney General (SDAG)</p> <p><b>Gainwell Technology Staff Present were as follows:</b>  Leid, Jovanna, Pharm.D.</p> <p><b>OptumRx Staff Present were as follows:</b></p>
	Present	Absent																														
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>																														
Adashek, Joseph, MD	<input type="checkbox"/>	<input checked="" type="checkbox"/>																														
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																														
Gonzalez, Elizabeth, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																														
Hautekeet, Mike, R.Ph	<input type="checkbox"/>	<input checked="" type="checkbox"/>																														
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>																														
Niezborala, Isabella, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																														
Singh, Aditi, MD	<input type="checkbox"/>	<input checked="" type="checkbox"/>																														
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																														

Agenda Item	Record	Notes
	<p>A quorum was present.</p> <p>Chairman Decerbo directed Kevin Whittington to proceed with the Financial Review of Drug classes with proposed changes up for review during the Second Quarter 2022 Silver State Scripts Board meeting.</p> <p>Mr. Whittington reminded the board members that the financial material presented is confidential and should not be discussed or disclosed outside this closed session of the Silver States Scripts Board meeting.</p> <p>Mr. Whittington presented the Financial Review of the Cardiovascular Agents - Antihypertensive Agents- Oral Vasodilators, noting the products with proposed changes in PDL status.</p> <p>Mr. Whittington presented the Financial Review of the Cardiovascular Agents - Antihypertensive Agents - Beta-Blockers class, noting the products with proposed changes in PDL status.</p> <p>Mr. Whittington presented the Financial Review of the Cardiovascular Agents – Antilipemic - Omega-3 Fatty Acids class, noting the products with proposed changes in PDL status.</p> <p>Mr. Whittington presented the Financial Review of the Neurological Agents – Anticonvulsants, noting the products with proposed changes in PDL status.</p> <p>Mr. Whittington presented the Financial Review of the Ophthalmic Agents - Antiglaucoma Agents class, noting the products with proposed changes in PDL status.</p>	<p>Kiriakopoulos, Amanda, Pharm.D.</p> <p>Whittington, Kevin, R.Ph.</p> <p>Chien, Michael, Pharm.D.</p> <p>Piccirilli, Annette</p>
<b>Open Public Meeting</b>		
<p>1. Call to Order and Roll Call</p>	<p>Chairman Decerbo called the meeting to order at 1:38 PM on June 23, 2022.</p> <p>Roll was taken by Chairman Decerbo.</p> <p style="text-align: right;">Present    Absent</p>	<p><b>The DHCFP Staff Present were as follows:</b></p> <p>Olsen, David, Social Services Chief III</p> <p>Gudino, Antonio, Social Services Program Specialist III</p>

Agenda Item	Record	Notes
	<p>Decerbo, Mark, Pharm.D. – Chair      <input checked="" type="checkbox"/>      <input type="checkbox"/></p> <p>Adashek, Joseph, MD      <input type="checkbox"/>      <input checked="" type="checkbox"/></p> <p>Crumby, Mark, Pharm.D.      <input checked="" type="checkbox"/>      <input type="checkbox"/></p> <p>Gonzalez, Elizabeth, Pharm.D.      <input checked="" type="checkbox"/>      <input type="checkbox"/></p> <p>Hautekeet, Mike, R.Ph      <input type="checkbox"/>      <input checked="" type="checkbox"/></p> <p>Khurana, Sapandeep, MD      <input checked="" type="checkbox"/>      <input type="checkbox"/></p> <p>Niezborala, Isabella, Pharm.D.      <input checked="" type="checkbox"/>      <input type="checkbox"/></p> <p>Singh, Aditi, MD      <input type="checkbox"/>      <input checked="" type="checkbox"/></p> <p>Ward, Kate, Pharm.D.      <input checked="" type="checkbox"/>      <input type="checkbox"/></p> <p>A quorum was present.</p>	<p>Griffin, Karen, SDAG Berntson, Kindra, Social Services Program Specialist II</p> <p><b>Gainwell Technology Staff Present were as follows:</b> Leid, Jovanna, Pharm.D.</p> <p><b>OptumRx Staff Present were as follows:</b> Kiriakopoulos, Amanda, Pharm.D. Whittington, Kevin, R.Ph. Piccirilli, Annette Medina, Daniel Chien, Michael, Pharm.D.</p> <p><b>The public attendee list is included as Attachment A.</b></p> <p><b>Note:</b> Participants may not have chosen to reveal their identity, and in the absence of a sign-in sheet, the accuracy of the attendee list is not assured.</p>
2. Public Comment on Any Matter on the Agenda.	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No public comment was offered.</p>	
3. Administrative		
a. For Possible Action: Review and Approve Meeting	<p>No corrections were offered.</p> <p>The minutes were approved by unanimous consent.</p>	

Agenda Item	Record	Notes
Minutes from March 24, 2022.		
b. Status Update by the DHCFP.	<p>Chief David Olsen discussed the start date of July 1, 2022, for Magellan Medicaid Administration as Nevada’s new Pharmacy Benefit Manager (PBM) and will facilitate the upcoming Silver State Scripts Board Meetings. He noted a new website (<a href="http://nevadamedicaid.magellan.rx.com">nevadamedicaid.magellan.rx.com</a>). He welcomed Dr. James Kim and the rest of his team present from Magellan.</p> <p>Chief Olsen discussed the recent approval for joining the National Medicaid Pooling Initiative (NMPI). The change will occur on October 1, 2022, and for more information regarding the NMPI, he was provided two contacts to share, Eileen Zimmer (<a href="mailto:eezimmer@magellanhealth.com">eezimmer@magellanhealth.com</a>) and Kristen Mhaloski (<a href="mailto:kmhaloski@magellanhealth.com">kmhaloski@magellanhealth.com</a>). For questions regarding rebates during the transition after July 1, Jeff Fanale (<a href="mailto:fnalej@magellanhealth.com">fnalej@magellanhealth.com</a>) can be contacted.</p> <p>Chief Olsen mentioned Senate Bill 325, which enables pharmacists to prescribe HIV preventative therapy and dispense oral contraceptive therapy without a prescription. On June 28 at 10:00 AM, a public hearing regarding the project will be held. This hearing will be one of the final steps required by CMS. For more information regarding the hearing, please refer to the public notices website listed on the agenda.</p> <p>Chief Olsen referred to a public comment made at the last Silver State Scripts Board meeting on March 24, 2022. Dr. Dana Trippy provided public comment regarding anti-obesity medications, and the state indicated they would follow up on these comments. Nevada Medicaid does not cover drugs used for the treatment of obesity. Nevada Medicaid is not required to cover these drugs by CMS, and many states and Medicare do not cover these agents. Nevada Medicaid is aware of the trend that more states are starting to offer limited coverage of agents and that there are efforts by advocates to change policy at a federal level as well. Chief Olsen described the steps for change within Nevada Medicaid. He noted that a fiscal impact</p>	

Agenda Item	Record	Notes												
	<p>review would need to be the first step and could be requested of legislators to perform. He commented that the next step would be a state legislation act, state plan amendment, and then final approval by CMS for coverage.</p> <p>Lastly, Chief Olsen noted that Benzaclin was added as a preferred drug in March. It is no longer manufactured and, as a result, will be removed from the PDL the next time it is updated.</p>													
4. Established Drug Classes Being Reviewed Due to the Release of New Generics														
a. For Possible Action: Discussion and possible adoption of Cardiovascular Agents - Antihypertensive Agents - Beta-Blockers.														
i. Public comment.	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No public comment was offered.</p>													
ii. Drug class review presentation by OptumRx.	<p>Dr. Amanda Kiriakopoulos discussed available generics.</p> <p>Dr. Kiriakopoulos recommended the Board consider the class clinically and therapeutically equivalent.</p>													
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	<p>Chairman Decerbo moved to accept the class as clinically and therapeutically equivalent.</p> <p>Board Member Khurana seconded the motion.</p> <p>A vote was held:</p> <table data-bbox="661 1279 1501 1388"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.											
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>											
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>											

Agenda Item	Record	Notes																												
	Gonzalez, Elizabeth, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> Khurana, Sapandeep, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> Niezborala, Isabella, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> Ward, Kate, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>																													
iv.      Presentation of recommendations for PDL inclusion by OptumRx.	Dr. Kiriakopoulos recommended adding nebivolol as non-preferred.																													
v.      Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	Board Member Ward moved to accept the proposed changes.  Chairman Decerbo seconded the motion.  A vote was held:  <table data-bbox="653 727 1503 1013"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Gonzalez, Elizabeth, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Niezborala, Isabella, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Gonzalez, Elizabeth, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Niezborala, Isabella, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																											
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Gonzalez, Elizabeth, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Niezborala, Isabella, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
b. For Possible Action: Discussion and possible adoption of Cardiovascular Agents - Antihypertensive Agents- Oral Vasodilators																														
i.      Public comment.	Telephonic and web comment was called for, and the phone lines were opened.  No public comment was offered.																													

Agenda Item	Record	Notes																												
ii. Drug class review presentation by OptumRx.	<p>Dr. Kiriakopoulos discussed the current generic availability within this drug class.</p> <p>Dr. Kiriakopoulos recommended the Board consider the class clinically and therapeutically equivalent.</p>																													
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	<p>Chairman Decerbo moved to accept the list is clinically and therapeutically equivalent.</p> <p>Board Member Ward seconded the motion.</p> <p>A vote was held:</p> <table border="0" data-bbox="653 630 1503 914"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Gonzalez, Elizabeth, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Niezborala, Isabella, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Gonzalez, Elizabeth, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Niezborala, Isabella, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																											
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Gonzalez, Elizabeth, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Niezborala, Isabella, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
iv. Presentation of recommendations for PDL inclusion by OptumRx.	<p>Dr. Kiriakopoulos recommended the Board add move bosentan to preferred and Tracleer to non-preferred.</p>																													
v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Board member Ward moved to accept the proposed changes.</p> <p>Board Member Crumby seconded the motion.</p> <p>A vote was held:</p> <table border="0" data-bbox="653 1247 1503 1401"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Gonzalez, Elizabeth, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Gonzalez, Elizabeth, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>													
	Yes	No	Abst.																											
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Gonzalez, Elizabeth, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											

Agenda Item	Record	Notes																												
	Khurana, Sapandeep, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> Niezborala, Isabella, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> Ward, Kate, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>																													
c. For Possible Action: Discussion and possible adoption of Cardiovascular Agents – Antilipemic - Omega-3 Fatty Acids																														
i. Public comment.	Telephonic and web comment was called for, and the phone lines were opened.  No public comment was offered.																													
ii. Drug class review presentation by OptumRx.	Dr. Kiriakopoulos discussed the current generic availability within this drug class.  Dr. Kiriakopoulos recommended the Board consider the class clinically and therapeutically equivalent.																													
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	Chairman Decerbo moved to accept the class as clinically and therapeutically equivalent.  Board Member Ward seconded the motion.  A vote was held: <table data-bbox="661 1079 1501 1362"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Gonzalez, Elizabeth, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Niezborala, Isabella, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Gonzalez, Elizabeth, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Niezborala, Isabella, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																											
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Gonzalez, Elizabeth, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Niezborala, Isabella, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											



Agenda Item	Record	Notes																												
iv. Presentation of recommendations for PDL inclusion by OptumRx.	Dr. Kiriakopoulos recommended icosapent be added as non-preferred.																													
v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Chairman Decerbo moved to accept the recommendation.</p> <p>Board Member Ward seconded the motion.</p> <p>A vote was held:</p> <table border="0" data-bbox="653 561 1503 842"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Gonzalez, Elizabeth, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Niezborala, Isabella, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Gonzalez, Elizabeth, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Niezborala, Isabella, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																											
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Gonzalez, Elizabeth, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Niezborala, Isabella, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
d. For Possible Action: Discussion and possible adoption of Neurological Agents – Anticonvulsants																														
i. Public comment.	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>Comment was provided by Mercedes Martin, a Medical Science Liaison with UCB, regarding Fintepla. She noted that as of March 2022, Fintepla is indicated for the treatment of Dravet Syndrome and Lennox-Gastaut syndrome (LGS). She discussed the LGS disease state. She provided Fintepla’s administration, dosing, and tolerability. In addition, clinical efficacy studies and safety information were presented. She thanked the Board for the maintenance of Fintepla as a preferred agent.</p>																													

Agenda Item	Record	Notes																												
ii. Drug class review presentation by OptumRx.	<p>Dr. Kiriakopoulos discussed available generics.</p> <p>Dr. Kiriakopoulos recommended the Board consider the class clinically and therapeutically equivalent.</p>																													
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class	<p>Chairman Decerbo moved to accept the class as clinically and therapeutically equivalent.</p> <p>Board Member Crumby seconded the motion.</p> <p>A vote was held:</p> <table border="0" data-bbox="653 597 1503 878"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Gonzalez, Elizabeth, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Niezborala, Isabella, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Gonzalez, Elizabeth, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Niezborala, Isabella, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																											
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Gonzalez, Elizabeth, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Niezborala, Isabella, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
iv. Presentation of recommendations for PDL inclusion by OptumRx.	<p>Dr. Kiriakopoulos recommended that Eprontia be added as non-preferred and lacosamide added as preferred. She recommended Vimpat and Lamictal XR be moved to non-preferred.</p>																													
v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Chairman Decerbo noted that he did not see lamotrigine ER on the preferred section of the PDL. Dr. Kiriakopoulos commented that lamotrigine as a chemical entity was on the preferred section and would include the ER formulation. Board Member Khurana asked that this be labeled clearly with the new PDL to avoid confusion. Dr. Kiriakopoulos commented that Magellan would be handling the new PDL and should be able to add to make sure both were listed.</p> <p>Board Member Ward moved to accept the recommendation noting that lamotrigine ER (generic Lamictal XR) would be maintained as preferred.</p>																													

Agenda Item	Record	Notes																												
	<p>Chairman Decerbo seconded the motion.</p> <p>A vote was held:</p> <table data-bbox="661 349 1501 625"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Gonzalez, Elizabeth, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Niezborala, Isabella, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Gonzalez, Elizabeth, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Niezborala, Isabella, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																											
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Gonzalez, Elizabeth, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Niezborala, Isabella, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
<p>e. For Possible Action: Discussion and possible adoption of Ophthalmic Agents - Antiglaucoma Agents</p>																														
<p>i. Public comment.</p>	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No public comment was offered.</p>																													
<p>ii. Drug class review presentation by OptumRx.</p>	<p>Dr. Kiriakopoulos discussed available generics.</p> <p>Dr. Kiriakopoulos recommended the Board consider the class clinically and therapeutically equivalent.</p>																													
<p>iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.</p>	<p>Chairman Decerbo moved to accept the class as clinically and therapeutically equivalent.</p> <p>Board Member Khurana seconded the motion.</p> <p>A vote was held:</p> <table data-bbox="661 1323 1501 1388"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																					
	Yes	No	Abst.																											
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											


Agenda Item	Record	Notes																																
	<table border="0"> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Gonzalez, Elizabeth, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Niezborala, Isabella, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </table>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Gonzalez, Elizabeth, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Niezborala, Isabella, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>													
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
Gonzalez, Elizabeth, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
Niezborala, Isabella, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
iv. Presentation of recommendations for PDL inclusion by OptumRx.	Dr. Kiriakopoulos recommended brimonidine/timolol be added as non-preferred.																																	
v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Board Member Ward moved to accept the recommendation.</p> <p>Chairman Decerbo seconded the motion.</p> <p>A vote was held:</p> <table border="0"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Adashek, Joseph, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Gonzalez, Elizabeth, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Niezborala, Isabella, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Gonzalez, Elizabeth, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Niezborala, Isabella, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																															
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
Gonzalez, Elizabeth, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
Niezborala, Isabella, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
5. OptumRx Reports: New Drugs to Market and New Line Extensions	Dr. Kiriakopoulos reviewed gene therapies, including Zynteglo, Roctavian, etranacogene dezaparvovec, and giroctocogene fitelparvovec for hematologic conditions.																																	
6. Closing Discussion																																		
a. Public comments on any subject.	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No public comment was offered.</p>																																	


Agenda Item	Record	Notes
	<p>Chairman Decerbo noted that written public comment was received regarding Hemangeol and teplizumab. He stated the information was reviewed by the Board. He wanted to ensure that the representatives for Hemangeol understood that while the product was not on the PDL, it is considered a covered drug with open access and no prior authorization.</p> <p>Chairman Decerbo thanked OptumRx and Gainwell Technologies for their efforts in serving the Board and the Medicaid patients in Nevada. Chairman Decerbo looks forward to continuing positive Board meetings with Magellan and Dr. Kim in the future.</p>	
<p>b. Date and location of the next meeting.</p>	<p>Chairman Decerbo confirmed that the next meeting is scheduled for September 22, 2022.</p>	
<p>c. Adjournment.</p>	<p>Chairman Decerbo adjourned the meeting at 2:10 PM.</p>	

**Attachment A – Members of the Public in Attendance**

Adler, Sarah, Belz & Case	Gonzales, Becky, ViiV	Mishra, Raj Magellan
Ashton, Elisa, JND	Haloski, Kristen, Magellan	Ou, Karen, Gilead
Berry, Kenneth, Alkermes	Hawkins, Tina, Magellan	Payne, Joe, Horizon Therapeutics
Booth, Robert, Abbvie	Kim, James, Magellan	Perez, Melissa, Magellan
Chow, Connie, Magellan	Kohlhoff, Chi Horizon Therapeutics	Ritter, Jean, Zealand
Cleveland, Joy, WellPoint	Kopp, Adam, Zogenix	Stout, Lee
Colabianchi, Jeana Sunovion	Lawrence, Henry, FidelisRx	Tran, Jimmy, Molina
Delgado, Jonathan, Novonordisk	Lim, Luke, WellPoint	Wensel, Brian, Sunovion
Domingo, Michelyn, WellPoint	Martin, Mercy, Zogenix	Willie, Brad, Neurocrine
Droese, Ben, Amgen	Martinez, Christian, Magellan	Zarob, Michael, Alkermes
Escame, David	McKenna, Brian, Oyster Point Rx	Chris
Fanale, Jeff, Magellan	Medina, Jessica	Gina

**Attachment B – Submitted Written Comment**

 Hemangeol.pdf

 Teplizumad.pdf